Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 2, 2015, Pages e79-

  Svenningsson, Anders ^a   Bergman, Joakim ^a   Dring, Ann ^a   Vågberg, Mattias ^a   Birgander, Richard ^a   Lindqvist, Thomas ^a   Gilthorpe, Jonathan ^a   Bergenheim, Tommy ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RITUXIMAB;

ANTIBIOTIC THERAPY; ARTICLE; B LYMPHOCYTE; CATHETER INFECTION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VERTIGO;

EID: 84949575977     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000079     Document Type: Article

References (15)

1. Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Exp Rev Neurother 2007;7:227-239.
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354: 899-910.
3. Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008;5:27-31.
4. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007;7:239-244.
5. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-2912.
6. Lassmann H. Multiple sclerosis: is there neurodegenera-tion independent from inflammation? J Neurol Sci 2007; 259:3-6.
7. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alz-heimer's disease. Peptides 2002;23:2223-2226.
8. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350-1356.
9. Perissinotti AJ, Reeves DJ. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother 2010;44:1633-1640.
10. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-468.
11. Lehmann-Horn K, Kinzel S, Feldmann L, et al. Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. Ann Clin Transl Neurol 2014;1:490-496.
12. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180: 63-70.
13. Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014;193:580-586.
14. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012;135:2925-2937.
15. Trbojevic-Cepe M, Brinar V, Pauro M, Vogrinc Z, Stambuk N. Cerebrospinal fluid complement activation in neurological diseases. J Neurol Sci 1998;154:173-181.